67 filings
8-K
SCPH
scPharmaceuticals Inc
13 Mar 24
Generated full-year net FUROSCIX® revenue of $13.6 million, at the upper end of the range provided in January
4:08pm
8-K
SCPH
scPharmaceuticals Inc
4 Jan 24
Gross-to-net (GTN) discount of approximately 18% from launch through the end of Q4
5:30pm
8-K
SCPH
scPharmaceuticals Inc
8 Nov 23
Results of Operations and Financial Condition
4:05pm
8-K
SCPH
scPharmaceuticals Inc
20 Sep 23
Entry into a Material Definitive Agreement
4:10pm
8-K
SCPH
scPharmaceuticals Inc
10 Aug 23
Results of Operations and Financial Condition
4:05pm
8-K
53juo0pplt1o6d
8 Jun 23
Submission of Matters to a Vote of Security Holders
4:11pm
8-K
jp04owxrj9ibzbfjrf
7 Jun 23
Other Events
7:00am
8-K
izy0z
10 May 23
Announced launch and commercial availability of FUROSCIX® on February 20th
4:08pm
8-K
irwe9v
22 Mar 23
Financial Results and Provides Business Update
4:15pm
8-K
wog7n34
10 Mar 23
Other Events
12:28pm
8-K
dl91ys1udlsfpgybc3k
19 Dec 22
Departure of Directors or Certain Officers
4:12pm
8-K
so2ye9eg
23 Nov 22
Other Events
4:12pm
8-K
rd269obqm40
9 Nov 22
Entered into a secured debt financing agreement for up to $100 million with funds managed by Oaktree
4:07pm
8-K
s44 tbnxco
14 Oct 22
Entry into a Material Definitive Agreement
4:10pm
8-K
ct9k2g8mqde7bd 46og
9 Aug 22
Announced FDA acceptance of FUROSCIX® New Drug Application and Prescription Drug User-Fee Act
7:14am
8-K
mgv2s4
12 Jul 22
Study results favor FUROSCIX® versus “treatment as usual” in composite primary endpoint and all secondary endpoints
8:08am
8-K
qhr8q
15 Jun 22
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
r0dac nv7x4
16 May 22
Continuing to ramp up commercial readiness activities in advance of an anticipated Q4 2022 launch of FUROSCIX®, if approved
7:26am
8-K
sqwjh685jxb62
16 May 22
Company preparing for Q4 commercial launch, if approved
7:14am
8-K
st12iz4qruu48 tto
11 Apr 22
Anticipates Q4 2022 commercial launch, if approved
7:44pm